The forecast for Canada’s modulators of the genital system and sex hormone sales market indicates a gradual decline from 2024 to 2028, with values decreasing from 589.1 million USD PPP in 2024 to 569.7 million USD PPP in 2028. The year-on-year variation shows negative growth, with slight annual declines averaging around -1% to -2% over these forecasted years. The compound annual growth rate (CAGR) further emphasizes this declining trend.
Future trends to watch for include potential shifts in healthcare policies, advancements in alternative therapies, and demographic changes that could impact demand within this market segment. Monitoring innovations and regulatory developments will be essential for future market dynamics.
